Compass Depreciation And Amortization vs Non Operating Income Net Other Analysis

CMPX Stock

USD 1.50 0.01 0.67%

Compass Therapeutics financial indicator trend analysis is way more than just evaluating Compass Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Compass Therapeutics is a good investment. Please check the relationship between Compass Therapeutics Depreciation And Amortization and its Non Operating Income Net Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Depreciation And Amortization vs Non Operating Income Net Other

Depreciation And Amortization vs Non Operating Income Net Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Compass Therapeutics Depreciation And Amortization account and Non Operating Income Net Other. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Compass Therapeutics' Depreciation And Amortization and Non Operating Income Net Other is -0.3. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Compass Therapeutics, assuming nothing else is changed. The correlation between historical values of Compass Therapeutics' Depreciation And Amortization and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Compass Therapeutics are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Depreciation And Amortization i.e., Compass Therapeutics' Depreciation And Amortization and Non Operating Income Net Other go up and down completely randomly.

Correlation Coefficient

-0.3

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Non Operating Income Net Other

Most indicators from Compass Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Compass Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.At this time, Compass Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 12.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.6M	1.9M	1.9M	1.7M
Interest Income	29K	2.4M	7.9M	8.3M

Depreciation And Amortization Interest Income

Compass Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		-0.87	0.42	0.67	0.9	0.87	-0.06	0.58	-0.27	-0.85	0.67	0.15	-0.09	0.07	-0.63	-0.75	1.0	-0.79	0.84	-0.77	0.68	0.92	-0.76	0.9	0.89	0.71
Short Long Term Debt Total	-0.87		-0.06	-0.61	-0.99	-1.0	0.45	-0.77	0.16	0.99	-0.54	-0.05	0.47	0.12	0.51	0.95	-0.88	0.94	-0.76	0.95	-0.5	-0.97	0.95	-0.99	-0.68	-0.88
Other Current Liab	0.42	-0.06		0.51	0.17	0.05	0.6	0.02	-0.64	0.02	-0.08	0.59	0.6	0.08	-0.45	-0.04	0.4	-0.11	0.0	-0.06	0.64	0.2	-0.04	0.17	0.51	0.03
Total Current Liabilities	0.67	-0.61	0.51		0.66	0.6	-0.19	0.54	-0.02	-0.58	0.24	-0.05	-0.2	-0.34	-0.22	-0.62	0.65	-0.57	0.39	-0.61	0.89	0.62	-0.59	0.67	0.45	0.53
Total Stockholder Equity	0.9	-0.99	0.17	0.66		0.99	-0.41	0.75	-0.21	-0.96	0.53	0.1	-0.43	-0.07	-0.5	-0.95	0.91	-0.96	0.72	-0.96	0.59	0.97	-0.96	1.0	0.69	0.87
Net Tangible Assets	0.87	-1.0	0.05	0.6	0.99		-0.45	0.73	-0.14	-0.98	0.57	0.03	-0.48	-0.06	-0.49	-0.94	0.88	-0.94	0.76	-0.95	0.5	0.96	-0.95	0.99	0.67	0.86
Property Plant And Equipment Net	-0.06	0.45	0.6	-0.19	-0.41	-0.45		-0.63	-0.51	0.47	-0.21	0.57	1.0	0.34	-0.45	0.61	-0.08	0.51	-0.22	0.58	-0.13	-0.4	0.59	-0.41	0.32	-0.63
Current Deferred Revenue	0.58	-0.77	0.02	0.54	0.75	0.73	-0.63		-0.05	-0.79	0.22	-0.08	-0.64	-0.61	-0.27	-0.87	0.59	-0.72	0.53	-0.83	0.46	0.82	-0.83	0.75	0.35	0.96
Net Debt	-0.27	0.16	-0.64	-0.02	-0.21	-0.14	-0.51	-0.05		0.05	0.34	-0.98	-0.51	-0.18	0.71	0.16	-0.27	0.25	0.16	0.19	-0.06	-0.2	0.19	-0.21	-0.48	-0.12
Retained Earnings	-0.85	0.99	0.02	-0.58	-0.96	-0.98	0.47	-0.79	0.05		-0.58	0.06	0.5	0.2	0.49	0.92	-0.86	0.88	-0.82	0.91	-0.45	-0.95	0.92	-0.96	-0.67	-0.88
Accounts Payable	0.67	-0.54	-0.08	0.24	0.53	0.57	-0.21	0.22	0.34	-0.58		-0.45	-0.24	0.36	-0.09	-0.36	0.68	-0.44	0.88	-0.39	0.39	0.58	-0.39	0.53	0.5	0.38
Cash	0.15	-0.05	0.59	-0.05	0.1	0.03	0.57	-0.08	-0.98	0.06	-0.45		0.57	0.2	-0.67	-0.05	0.14	-0.14	-0.28	-0.08	-0.05	0.06	-0.08	0.1	0.4	-0.03
Non Current Assets Total	-0.09	0.47	0.6	-0.2	-0.43	-0.48	1.0	-0.64	-0.51	0.5	-0.24	0.57		0.35	-0.42	0.62	-0.11	0.53	-0.25	0.6	-0.14	-0.43	0.61	-0.44	0.29	-0.64
Non Currrent Assets Other	0.07	0.12	0.08	-0.34	-0.07	-0.06	0.34	-0.61	-0.18	0.2	0.36	0.2	0.35		0.02	0.25	0.07	-0.03	0.01	0.16	-0.09	-0.12	0.16	-0.07	0.1	-0.37
Other Assets	-0.63	0.51	-0.45	-0.22	-0.5	-0.49	-0.45	-0.27	0.71	0.49	-0.09	-0.67	-0.42	0.02		0.35	-0.63	0.36	-0.42	0.35	-0.08	-0.5	0.36	-0.49	-0.88	-0.32
Long Term Debt	-0.75	0.95	-0.04	-0.62	-0.95	-0.94	0.61	-0.87	0.16	0.92	-0.36	-0.05	0.62	0.25	0.35		-0.76	0.96	-0.58	1.0	-0.53	-0.93	0.99	-0.95	-0.48	-0.95
Cash And Short Term Investments	1.0	-0.88	0.4	0.65	0.91	0.88	-0.08	0.59	-0.27	-0.86	0.68	0.14	-0.11	0.07	-0.63	-0.76		-0.8	0.85	-0.78	0.67	0.93	-0.77	0.91	0.89	0.72
Common Stock Total Equity	-0.79	0.94	-0.11	-0.57	-0.96	-0.94	0.51	-0.72	0.25	0.88	-0.44	-0.14	0.53	-0.03	0.36	0.96	-0.8		-0.57	0.98	-0.55	-0.92	0.98	-0.96	-0.52	-0.87
Common Stock Shares Outstanding	0.84	-0.76	0.0	0.39	0.72	0.76	-0.22	0.53	0.16	-0.82	0.88	-0.28	-0.25	0.01	-0.42	-0.58	0.85	-0.57		-0.58	0.41	0.79	-0.58	0.72	0.73	0.62
Non Current Liabilities Total	-0.77	0.95	-0.06	-0.61	-0.96	-0.95	0.58	-0.83	0.19	0.91	-0.39	-0.08	0.6	0.16	0.35	1.0	-0.78	0.98	-0.58		-0.54	-0.94	1.0	-0.96	-0.5	-0.93
Other Current Assets	0.68	-0.5	0.64	0.89	0.59	0.5	-0.13	0.46	-0.06	-0.45	0.39	-0.05	-0.14	-0.09	-0.08	-0.53	0.67	-0.55	0.41	-0.54		0.61	-0.52	0.59	0.42	0.5
Other Stockholder Equity	0.92	-0.97	0.2	0.62	0.97	0.96	-0.4	0.82	-0.2	-0.95	0.58	0.06	-0.43	-0.12	-0.5	-0.93	0.93	-0.92	0.79	-0.94	0.61		-0.93	0.97	0.71	0.92
Total Liab	-0.76	0.95	-0.04	-0.59	-0.96	-0.95	0.59	-0.83	0.19	0.92	-0.39	-0.08	0.61	0.16	0.36	0.99	-0.77	0.98	-0.58	1.0	-0.52	-0.93		-0.96	-0.49	-0.93
Net Invested Capital	0.9	-0.99	0.17	0.67	1.0	0.99	-0.41	0.75	-0.21	-0.96	0.53	0.1	-0.44	-0.07	-0.49	-0.95	0.91	-0.96	0.72	-0.96	0.59	0.97	-0.96		0.69	0.87
Property Plant And Equipment Gross	0.89	-0.68	0.51	0.45	0.69	0.67	0.32	0.35	-0.48	-0.67	0.5	0.4	0.29	0.1	-0.88	-0.48	0.89	-0.52	0.73	-0.5	0.42	0.71	-0.49	0.69		0.45
Short Long Term Debt	0.71	-0.88	0.03	0.53	0.87	0.86	-0.63	0.96	-0.12	-0.88	0.38	-0.03	-0.64	-0.37	-0.32	-0.95	0.72	-0.87	0.62	-0.93	0.5	0.92	-0.93	0.87	0.45

Click cells to compare fundamentals

Compass Therapeutics Account Relationship Matchups

Compass Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.4M	51.9M	153.8M	199.6M	156.9M	120.5M
Short Long Term Debt Total	14.9M	9.3M	4.0M	2.9M	1.7M	1.6M
Other Current Liab	494K	510K	7.9M	8.3M	(1.6M)	(1.5M)
Total Current Liabilities	9.8M	10.1M	10.6M	16.2M	7.8M	11.5M
Total Stockholder Equity	(118.6M)	39.9M	140.1M	181.6M	148.5M	156.0M
Net Tangible Assets	(118.6M)	39.9M	140.1M	181.6M	208.9M	219.3M
Property Plant And Equipment Net	3.8M	1.1M	6.3M	4.5M	2.7M	3.2M
Net Debt	(10.4M)	(37.7M)	(140.5M)	(32.0M)	(22.5M)	(23.6M)
Retained Earnings	(121.9M)	(151.4M)	(233.6M)	(272.8M)	(315.3M)	(299.5M)
Accounts Payable	629K	1.1M	867K	3.4M	4.1M	2.2M
Cash	25.3M	47.1M	144.5M	34.9M	24.2M	44.5M
Non Current Assets Total	4.1M	1.7M	6.7M	4.9M	3.0M	3.5M
Other Assets	392K	583K	0.0	320K	288K	267.5K
Cash And Short Term Investments	25.3M	47.1M	144.5M	186.6M	152.5M	112.5M
Common Stock Total Equity	3.3M	5K	10K	13K	11.7K	11.1K
Liabilities And Stockholders Equity	30.4M	51.9M	153.8M	199.6M	156.9M	120.5M
Non Current Liabilities Total	139.2M	1.9M	3.0M	1.8M	536.0K	509.2K
Other Current Assets	935K	3.1M	2.6M	8.2M	1.4M	1.3M
Other Stockholder Equity	3.3M	191.3M	373.7M	454.7M	463.8M	273.3M
Total Liab	149.0M	12.0M	13.7M	18.0M	8.3M	7.9M
Net Invested Capital	(103.7M)	49.3M	140.1M	181.6M	148.5M	156.0M
Property Plant And Equipment Gross	3.8M	1.1M	11.4M	10.1M	8.9M	7.5M
Total Current Assets	26.2M	50.2M	147.1M	194.8M	153.9M	115.7M
Capital Stock	3.3M	5K	10K	13K	11.7K	11.1K
Net Working Capital	16.4M	40.1M	136.5M	178.6M	146.1M	104.2M
Short Term Debt	5.6M	7.5M	989K	1.1M	1.2M	1.1M
Common Stock	3.3M	5K	10K	13K	11.7K	11.1K
Property Plant Equipment	3.8M	1.1M	6.3M	1.6M	1.4M	1.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Compass Depreciation And Amortization vs Non Operating Income Net Other Analysis

Depreciation And Amortization vs Non Operating Income Net Other

Depreciation And Amortization vs Non Operating Income Net Other Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Non Operating Income Net Other

Compass Therapeutics fundamental ratios Correlations

Compass Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Compass Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Compass Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Non Current Liabilities Total	+ 1.0	Long Term Debt
Total Liab	+ 1.0	Non Current Liabilities Total
Retained Earnings	+ 0.99	Short Long Term Debt Total

Net Tangible Assets	- 1.0	Short Long Term Debt Total
Net Invested Capital	- 0.99	Short Long Term Debt Total
Total Stockholder Equity	- 0.99	Short Long Term Debt Total
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Net Tangible Assets
Other Stockholder Equity	- 0.97	Short Long Term Debt Total